Loading...
PCK logo

PainChek LimitedASX:PCK Stock Report

Market Cap AU$101.4m
Share Price
AU$0.049
My Fair Value
1Y69.0%
7D-16.9%
Portfolio Value
View

PainChek Limited

ASX:PCK Stock Report

Market Cap: AU$101.4m

PainChek (PCK) Stock Overview

Develops and commercialized mobile medical device applications that provides pain assessment for individuals in Australia, the United Kingdom, and internationally. More details

PCK fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

PCK Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

PainChek Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for PainChek
Historical stock prices
Current Share PriceAU$0.049
52 Week HighAU$0.10
52 Week LowAU$0.024
Beta0.45
1 Month Change-3.92%
3 Month Change22.50%
1 Year Change68.97%
3 Year Change48.48%
5 Year Change-45.56%
Change since IPO-16.95%

Recent News & Updates

Recent updates

We're Keeping An Eye On PainChek's (ASX:PCK) Cash Burn Rate

Jul 04
We're Keeping An Eye On PainChek's (ASX:PCK) Cash Burn Rate

Is PainChek (ASX:PCK) In A Good Position To Invest In Growth?

Feb 08
Is PainChek (ASX:PCK) In A Good Position To Invest In Growth?

Will PainChek (ASX:PCK) Spend Its Cash Wisely?

Jul 05
Will PainChek (ASX:PCK) Spend Its Cash Wisely?

Companies Like PainChek (ASX:PCK) Can Afford To Invest In Growth

Jan 26
Companies Like PainChek (ASX:PCK) Can Afford To Invest In Growth

We're Interested To See How PainChek (ASX:PCK) Uses Its Cash Hoard To Grow

Sep 07
We're Interested To See How PainChek (ASX:PCK) Uses Its Cash Hoard To Grow

When Can We Expect A Profit From PainChek Limited (ASX:PCK)?

May 07
When Can We Expect A Profit From PainChek Limited (ASX:PCK)?

PainChek (ASX:PCK) Is In A Strong Position To Grow Its Business

Mar 01
PainChek (ASX:PCK) Is In A Strong Position To Grow Its Business

Market Sentiment Around Loss-Making PainChek Limited (ASX:PCK)

Nov 20
Market Sentiment Around Loss-Making PainChek Limited (ASX:PCK)

Shareholder Returns

PCKAU Healthcare ServicesAU Market
7D-16.9%-0.8%0.3%
1Y69.0%56.2%9.9%

Return vs Industry: PCK exceeded the Australian Healthcare Services industry which returned 55.5% over the past year.

Return vs Market: PCK exceeded the Australian Market which returned 10.2% over the past year.

Price Volatility

Is PCK's price volatile compared to industry and market?
PCK volatility
PCK Average Weekly Movement13.4%
Healthcare Services Industry Average Movement9.7%
Market Average Movement9.5%
10% most volatile stocks in AU Market20.5%
10% least volatile stocks in AU Market3.4%

Stable Share Price: PCK has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: PCK's weekly volatility (13%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/aPhilip Daffaswww.painchek.com

PainChek Limited develops and commercialized mobile medical device applications that provides pain assessment for individuals in Australia, the United Kingdom, and internationally. The company offers PainChek, a clinically validated and regulatory cleared pain assessment technology that uses cameras in smartphones for a facial scan that is analyzed using facial recognition software to indicate the presence of pain. It serves patients suffering with dementia and pre-verbal infants; and the aged care, disability, home care, hospital, and infant sectors.

PainChek Limited Fundamentals Summary

How do PainChek's earnings and revenue compare to its market cap?
PCK fundamental statistics
Market capAU$101.36m
Earnings (TTM)-AU$7.67m
Revenue (TTM)AU$3.36m
30.1x
P/S Ratio
-13.2x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PCK income statement (TTM)
RevenueAU$3.36m
Cost of RevenueAU$2.36m
Gross ProfitAU$997.74k
Other ExpensesAU$8.67m
Earnings-AU$7.67m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.0037
Gross Margin29.67%
Net Profit Margin-228.18%
Debt/Equity Ratio0%

How did PCK perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/24 08:38
End of Day Share Price 2025/10/24 00:00
Earnings2025/06/30
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PainChek Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Martyn JacobsCanaccord Genuity
Ian MartinNew Street Research LLP